Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.48 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.46 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.46 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.45 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.42 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | USP7 | Q93009 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8065806 | 0.99 | POLB (0.50) | POLBCASP3SENP7SENP6KCNH2 | |
| Hydrochloric Acid SCHEMBL917532 | 0.76 | DRD2 (0.46) | KCNH2TAAR1DRD2HTR2ASLC6A3 | |
| Hydrochloric Acid SCHEMBL4236449 | 0.76 | POLB (0.68) | POLBCASP3SENP7SENP6KCNH2 | |
| Hydrochloric Acid SCHEMBL917850 | 0.75 | ACHE (0.47) | TAAR1 | |
| Hydrochloric Acid SCHEMBL441062 | 0.74 | USP7 (0.72) | POLBCASP3SENP7SENP6KCNH2 | |
| Hydrochloric Acid SCHEMBL1711121 | 0.74 | DRD2 (0.63) | DRD2HTR2ADRD3HTR1A | |
| SCHEMBL1486955 | 0.74 | NPC1 (0.49) | DRD2HTR2ADRD3 | |
| SCHEMBL8056662 | 0.74 | DRD2 (0.47) | KCNH2TAAR1DRD2HTR2ANR1H4 | |
| SCHEMBL8061783 | 0.73 | ACHE (0.48) | TAAR1 | |
| SCHEMBL29291624 | 0.73 | DRD2 (0.46) | KCNH2TAAR1DRD2HTR2ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518939-B2 | 6-pyrimidinyl-pyrimid-4-one derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-2197877-B1 | 3-METHYL-2- ( (2S) -2- (4- (3-METHYL-1, 2, 4-OXADIAZOL-5-YL) PHENYL) MORPHOLINO) -6- (PYRIMIDIN-4-YL) PYRIMIDIN-4 (3H) -ONE AS TAU PROTEIN KINASE INHIBITOR | SANOFI SA (FR) | 2013-05-15 | — | — | EP | disclosed |
| EP-2193129-B1 | 6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-8288383-B2 | 3-methyl-2- ( (2S) -2- (4- (3-methyl-L, 2, 4-oxadiazol-5-YL) phenyl) morpholino) -6- (pyrim-idin-4-yl) pyrimidin-4 (3H) -one as tau protein kinase inhibitor | SANOFI (FR) | 2012-10-16 | — | — | US | disclosed |
| US-20120252812-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | SANOFI-AVENTIS (FR) | 2012-10-04 | — | — | US | disclosed |
| US-8198437-B2 | 6-pyrimidinyl-pyrimid-4-one derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20110021773-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-27 | — | — | US | disclosed |
| US-20110003988-A1 | 3-METHYL-2- ( (2S) -2- (4- (3-METHYL-L, 2, 4-0XADIAZ0L-5-YL) PHENYL) MORPHOLINO) -6- (PYRIM-IDIN-4-YL) PYRIMIDIN-4 (3H) -ONE AS TAU PROTEIN KINASE INHIBITOR | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | US | disclosed |
| EP-2193129-A1 | 6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-06-09 | — | — | EP | disclosed |
| EP-2078717-A1 | 6-Pyrimidinyl-pyrimid-2-one derivative | sanofi-aventis (FR) | 2009-07-15 | — | — | EP | disclosed |
| WO-2009035162-A1 | 6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252812-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | MAPT, PSEN1, PSEN2 | KCNH2 3571/4885DRD2 3846/4885HTR2A 3004/4885 |
| US-20110003988-A1 | 3-METHYL-2- ( (2S) -2- (4- (3-METHYL-L, 2, 4-0XADIAZ0L-5-YL) PHENYL) MORPHOLINO) -6- (PYRIM-IDIN-4-YL) PYRIMIDIN-4 (3H) -ONE AS TAU PROTEIN KINASE INHIBITOR | MAPT, PSEN2, PSEN1 | KCNH2 2328/4885DRD2 4155/4885HTR2A 2149/4885 |
| US-20110021773-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | MAPT, PSEN1, PSEN2 | KCNH2 3571/4885DRD2 3846/4885HTR2A 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.